Patient Goals and Characteristics Play an Outsized Role in Determining First-Line Treatment for mCRC
Selecting the optimal frontline treatment regimen for patients with unresectable metastatic colorectal cancer requires careful consideration of multiple patient and treatment characteristics.
Biomarkers Continue to Play a Pivotal Role in Treatment Decisions in Metastatic CRC
The expansion of the treatment armamentarium has emphasized the importance of genetic testing in patients with metastatic colorectal cancer, according to Christopher Lieu, MD, who added continued developments in the field have produced additional treatment regimens across patient subsets.
Messersmith Makes Sense of the Novel Approaches on the Rise in GI MalignanciesMarch 23rd 2021
The pipeline of new agents in gastrointestinal cancers is robust, with the emergence of several antibody-drug conjugates, KRAS G12C inhibitors, and novel TKI/immune checkpoint inhibitor combinations.
The Future of Biliary Tract Treatment Lies in Molecular ProfilingMarch 22nd 2021
Although the genetic makeup of biliary tract cancer is rich, only recently has the field been able to show the benefit of treating patients with effective targeted agents, such as pemigatinib and ivosidenib in the advanced setting.
Debate Continues on Optimal Neoadjuvant Regimen in Resectable Pancreatic CancerApril 2nd 2020
Michael A. Choti, MD, MBA, FACS, discusses the role of radiation therapy in neoadjuvant therapy for resectable pancreatic cancer, the many benefits of neoadjuvant therapy over up-front surgery, and minimally invasive surgical procedures that are coming to the forefront in this disease.
Novel Approaches to Build on Checkpoint Inhibition in GI CancersApril 1st 2020
Despite some success stories, most gastrointestinal cancers do not respond to single-agent, or even double-agent, immune checkpoint inhibition, Neeha Zaidi, MD, said in a presentation during the 5th Annual School of Gastrointestinal Oncology™ (SOGO®) conference.
Management, Etiology of Younger Patients With CRC Require Deeper UnderstandingMarch 31st 2020
The etiology and overall management of patients with early-onset colorectal cancer needs to be better understood and personalized, respectively, explained Andrea Cercek, MD, in a presentation during the 5th Annual School of Gastrointestinal Oncology™.
Immunotherapy Doubts Fading in GI CancersApril 26th 2016
Immunotherapy approaches are showing early signs of activity against a range of gastrointestinal cancers, defying the skeptical view that these tumors would not respond to the emerging agents succeeding in other malignancies.
Dr. Douglas Evans on Neadjuvant Therapy for Pancreas CancerApril 26th 2016
Douglas B. Evans, MD, FACS, Chair, Professor, Donald C. Ausman Family Foundation Professor of Surgery, Medical College of Wisconsin, discusses how to appropriately sequence therapies for pancreatic cancer.
Precision Medicine Vital to Value-Based GI Cancer CareApril 23rd 2016
Cancer care is shifting from a consumption to a value-based model, and precision oncology should play a vital role in that process by helping to deliver more effective therapies with more manageable pricing profiles.